Pangenomic Health Valuation
Is LL3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of LL3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate LL3's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate LL3's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LL3?
Key metric: As LL3 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is LL3's PB Ratio? | |
|---|---|
| PB Ratio | -0.9x |
| Book | -CA$1.48m |
| Market Cap | CA$4.48m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -3.5x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does LL3's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1x | ||
AJ91 DocCheck | 1.1x | n/a | €41.4m |
M3V MeVis Medical Solutions | 2.5x | n/a | €45.1m |
MF6 MagForce | 0.1x | 149.0% | €3.6m |
EIF MedNation | 0.4x | n/a | €4.7m |
LL3 Pangenomic Health | n/a | n/a | €4.5m |
Price-To-Book vs Peers: LL3 has negative equity and a Price-To-Book Ratio (-0.9x) compared to the peer average (1.3x).
Price to Book Ratio vs Industry
How does LL3's PB Ratio compare vs other companies in the European Healthcare Services Industry?
| 6 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 6 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: LL3 has negative equity and a Price-To-Book Ratio (-0.9x) compared to the European Healthcare Services industry average (2.7x).
Price to Book Ratio vs Fair Ratio
What is LL3's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -0.9x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate LL3's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Fagron
€1.3b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
4A5
€18.12
7D
-3.1%
1Y
5.2%
Shandong Weigao Group Medical Polymer
HK$20.6b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.53
7D
-13.2%
1Y
-37.9%
LNA Santé
€243.4m
Engages in the management and operation of health establishments.
2N3
€23.45
7D
-5.6%
1Y
16.1%